Non-Small Cell Lung Cancer ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Non-Small Cell Lung Cancer ' Pipeline Review, H2 2012
Published on September 2012

Report Summary


Summary

Global Markets Direct's, 'Non-Small Cell Lung Cancer - Pipeline Review, Global Markets Direct's, 'Non-Small Cell Lung Cancer -
Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the
therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. Non-Small
Cell Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
- A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based
on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of
Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Non-Small Cell Lung Cancer ' Pipeline Review, H2 2012 (From Slideshare) Page 1/12


Table of Content

Table of Contents
Table of Contents 2
List of Tables 25
List of Figures 33
Introduction 34
Global Markets Direct Report Coverage 34
Non-Small Cell Lung Cancer Overview 35
Therapeutics Development 36
An Overview of Pipeline Products for Non-Small Cell Lung Cancer 36
Non-Small Cell Lung Cancer Therapeutics under Development by Companies 38
Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes 50
Late Stage Products 72
Comparative Analysis 72
Mid Clinical Stage Products 73
Early Clinical Stage Products 74
Discovery and Pre-Clinical Stage Products 75
Non-Small Cell Lung Cancer Therapeutics ' Products under Development by Companies 76
Non-Small Cell Lung Cancer Therapeutics ' Products under Investigation by Universities/Institutes 101
Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development 160
Bristol-Myers Squibb Company 160
Boehringer Ingelheim GmbH 161
F. Hoffmann-La Roche Ltd. 162
Kyowa Hakko Kirin Co., Ltd. 163
Abbott Laboratories 164
Biogen Idec Inc. 165
Helix BioPharma Corp. 166
Amgen Inc. 167
Sanofi-Aventis 168
AstraZeneca PLC 169
Eli Lilly and Company 170
GlaxoSmithKline plc 172
Genentech, Inc. 173
Antigenics, Inc. 174
Inovio Biomedical Corporation 175
MedImmune LLC 176
Isis Pharmaceuticals, Inc. 177
Daiichi Sankyo Company, Ltd 178
Merck & Co., Inc. 179
Infinity Pharmaceuticals, Inc. 180
Takeda Pharmaceutical Company Limited 181
YM BioSciences Inc. 182



Celltrion, Inc. 183
ZIOPHARM Oncology, Inc. 184
Millennium Pharmaceuticals, Inc. 185
Novartis AG 186
Astellas Pharma Inc. 187
Biocon Limited 188
Cephalon, Inc. 189
Chong Kun Dang Pharmaceutical 190
Chugai Pharmaceutical Co. Ltd 191
Eisai Co., Ltd. 192
Human Genome Sciences, Inc. 193
OSI Pharmaceuticals, Inc. 194
Pfizer Inc. 195
Taiho Pharmaceutical Co., Ltd. 196
Teva Pharmaceutical Industries Limited 197
Yakult Honsha Co., Ltd. 198
Cell Therapeutics, Inc. 199
Exelixis, Inc. 200
Aduro BioTech 201
Cyclacel Pharmaceuticals Inc. 202
Alfacell Corporation 203
Celgene Corporation 204
Onyx Pharmaceuticals, Inc. 205
Bayer AG 206
Geron Corporation 207
Aeolus Pharmaceuticals, Inc. 208
Merck KGaA 209
EntreMed, Inc. 210
Hana Biosciences, Inc. 211
Celldex Therapeutics, Inc. 212
AEterna Zentaris Inc. 213
ImmunoCellular Therapeutics, Ltd. 214
Idera Pharmaceuticals, Inc. 215
Ariad Pharmaceuticals, Inc. 216
Lorus Therapeutics Inc 217
Benitec Ltd. 218
MethylGene Inc 219
Northwest Biotherapeutics, Inc. 220
Novogen Limited 221
Cleveland BioLabs, Inc. 222
Oncolytics Biotech Inc. 223
Oncothyreon Inc 224
Compugen Ltd. 225
OXiGENE, Inc. 226
Neotropix, Inc. 275
Mersana Therapeutics, Inc. 276
Optimum Therapeutics, LLC 308
PharmaTech International, Inc. 309



Non-Small Cell Lung Cancer ' Therapeutics Assessment 310
Assessment by Monotherapy Products 310
Assessment by Combination Products 311
Assessment by Route of Administration 312
Assessment by Molecule Type 314
Drug Profiles 317
eribulin mesylate - Drug Profile 317
Product Description 317
Mechanism of Action 317
R&D Progress 317
motesanib diphosphate - Drug Profile 319
R&D Progress 319
Gemcitabine + Cisplatin - Drug Profile 372
R&D Progress 372
aspirin - Drug Profile 373
R&D Progress 373
Carboplatin + Paclitaxel - Drug Profile 374
R&D Progress 374
Alimta + Cisplatin - Drug Profile 376
R&D Progress 376
Pemetrexed + Cisplatin - Drug Profile 378
R&D Progress 378
Gemcitabine + Paclitaxel - Drug Profile 379
R&D Progress 379
dexamethasone acetate - Drug Profile 381
R&D Progress 381
Paclitaxel + Carboplatin - Drug Profile 382
R&D Progress 382
bevacizumab + pemetrexed + cisplatin - Drug Profile 383



R&D Progress 383
Paclitaxel + Pemetrexed - Drug Profile 488
R&D Progress 488
erlotinib hydrochloride - Drug Profile 490
R&D Progress 490
cisplatin - Drug Profile 523
R&D Progress 523
Carboplatin + Radiation Therapy - Drug Profile 525
R&D Progress 525
R&D Progress 526
R&D Progress 528
IMC-1121B + Docetaxel - Drug Profile 530
R&D Progress 530
R&D Progress 532
Cisplatin + Vindesine + Mitomycin + Radiation Therapy - Drug Profile 533
R&D Progress 533
Mitomycin + Vindesine + Cisplatin + Radiation Therapy - Drug Profile 535
R&D Progress 535
Endostar + Vinorelbine + Cisplatin - Drug Profile 617
R&D Progress 617
Acetylcarnitine + Cisplatin - Drug Profile 619



R&D Progress 619
Cetuximab + Paclitaxel + Carboplatin + Bevacizumab - Drug Profile 620
R&D Progress 620
Cisplatin + Vinorelbine - Drug Profile 622
R&D Progress 622
Non-Small Cell Lung Cancer Therapeutics ' Drug Profile Updates 623
Non-Small Cell Lung Cancer Therapeutics ' Discontinued Products 668
Non-Small Cell Lung Cancer Therapeutics - Dormant Products 683
Non-Small Cell Lung Cancer ' Product Development Milestones 747
Featured News & Press Releases 747
Sep 20, 2012: Boehringer Ingelheim Presents Data On Anti-cancer Drug Afatinib At ESMO 2012 Congress 747
Sep 20, 2012: Boehringer Ingelheim Submits Marketing Authorization Application For Afatinib In Europe 748
Sep 18, 2012: Synta Pharma To Present Interim Results From GALAXY Trial At ESMO 2012 749
Sep 17, 2012: Ariad Announces Presentation Of Initial Data On AP26113 At ESMO 2012 Congress Of European Society For Medical
Oncology 749
Sep 17, 2012: Exelixis Announces Data Presentations On Cabozantinib At ESMO 2012 Congress 750
Sep 17, 2012: Pfizer To Present New Data On Crizotinib In Lung Cancer At European Society For Medical Oncology 2012 Congress
750
Sep 17, 2012: Bayer To Present Data On Nexavar At ESMO 2012 Congress 751
Sep 13, 2012: Boehringer Ingelheim Announces Afatinib Expanded Access Program For Lung Cancer Patients 752
Sep 07, 2012: Peregrine Announces Presentation Of Interim Results From Phase II Trial In Second-Line Non-Small Cell Lung Cancer
753
Sep 06, 2012: Sarah Cannon Research Institute Presents Clinical And Safety Data Of Lung Cancer Drug At 2012 Chicago
Multidisciplinary Symposium In Thoracic Oncology 754
Appendix 755
Methodology 755
Coverage 755
Secondary Research 755
Primary Research 755
Expert Panel Validation 755
Contact Us 756
Disclaimer 756

List of Tables

Number of Products Under Development for Non-Small Cell Lung Cancer, H2 2012 36
Products under Development for Non-Small Cell Lung Cancer ' Comparative Analysis, H2 2012 37
Number of Products under Development by Companies, H2 2012 39
Number of Products under Development by Companies, H2 2012 (Contd..1) 40



Number of Products under Investigation by Universities/Institutes, H2 2012 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 52
Comparative Analysis by Late Stage Development, H2 2012 72
Comparative Analysis by Mid Clinical Stage Development, H2 2012 73
Comparative Analysis by Early Clinical Stage Development, H2 2012 74
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 75
Products under Development by Companies, H2 2012 76
Products under Development by Companies, H2 2012 (Contd..1) 77



Products under Investigation by Universities/Institutes, H2 2012 101
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 102



Bristol-Myers Squibb Company, H2 2012 160
Boehringer Ingelheim GmbH, H2 2012 161
F. Hoffmann-La Roche Ltd., H2 2012 162
Kyowa Hakko Kirin Co., Ltd., H2 2012 163
Abbott Laboratories, H2 2012 164
Biogen Idec Inc., H2 2012 165
Helix BioPharma Corp., H2 2012 166
Amgen Inc., H2 2012 167
Sanofi-Aventis, H2 2012 168
AstraZeneca PLC, H2 2012 169
Eli Lilly and Company, H2 2012 170
GlaxoSmithKline plc, H2 2012 172
Genentech, Inc., H2 2012 173
Antigenics, Inc., H2 2012 174
Inovio Biomedical Corporation, H2 2012 175
MedImmune LLC, H2 2012 176
Isis Pharmaceuticals, Inc., H2 2012 177
Daiichi Sankyo Company, Ltd, H2 2012 178
Merck & Co., Inc., H2 2012 179
Infinity Pharmaceuticals, Inc., H2 2012 180
Takeda Pharmaceutical Company Limited, H2 2012 181
YM BioSciences Inc., H2 2012 182
Celltrion, Inc., H2 2012 183
ZIOPHARM Oncology, Inc., H2 2012 184
Millennium Pharmaceuticals, Inc., H2 2012 185
Novartis AG, H2 2012 186
Astellas Pharma Inc., H2 2012 187
Biocon Limited, H2 2012 188
Cephalon, Inc., H2 2012 189
Chong Kun Dang Pharmaceutical, H2 2012 190



Chugai Pharmaceutical Co. Ltd, H2 2012 191
Eisai Co., Ltd., H2 2012 192
Human Genome Sciences, Inc., H2 2012 193
OSI Pharmaceuticals, Inc., H2 2012 194
Pfizer Inc., H2 2012 195
Taiho Pharmaceutical Co., Ltd., H2 2012 196
Teva Pharmaceutical Industries Limited, H2 2012 197
Yakult Honsha Co., Ltd., H2 2012 198
Cell Therapeutics, Inc., H2 2012 199
Exelixis, Inc., H2 2012 200
Aduro BioTech, H2 2012 201
Cyclacel Pharmaceuticals Inc., H2 2012 202
Alfacell Corporation, H2 2012 203
Celgene Corporation, H2 2012 204
Onyx Pharmaceuticals, Inc., H2 2012 205
Bayer AG, H2 2012 206
Geron Corporation, H2 2012 207
Aeolus Pharmaceuticals, Inc., H2 2012 208
Merck KGaA, H2 2012 209
EntreMed, Inc., H2 2012 210
Hana Biosciences, Inc., H2 2012 211
Celldex Therapeutics, Inc., H2 2012 21

List of Figures

Number of Products under Development for Non-Small Cell Lung Cancer, H2 2012 36
Products under Development for Non-Small Cell Lung Cancer ' Comparative Analysis, H2 2012 37
Products under Development by Companies, H2 2012 38
Products under Investigation by Universities/Institutes, H2 2012 50
Late Stage Products, H2 2012 72
Mid Clinical Stage Products, H2 2012 73
Early Clinical Stage Products, H2 2012 74
Discovery and Pre-Clinical Stage Products, H2 2012 75
Assessment by Monotherapy Products, H2 2012 310
Assessment by Combination Products, H2 2012 311
Assessment by Route of Administration, H2 2012 312
Assessment by Stage and Route of Administration, H2 2012 313
Assessment by Molecule Type, H2 2012 314
Assessment by Stage and Molecule Type, H2 2012 315


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 500.00 Quantity: _____

Site License--USD 5 000.00 Quantity: _____

Corporate License--USD 7 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Non-Small Cell Lung Cancer ' Pipeline Review, H2 2012

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Andere mochten auch

Andere mochten auch (18)

Mehr von ReportLinker.com

Mehr von ReportLinker.com (20)

Non-Small Cell Lung Cancer ' Pipeline Review, H2 2012